Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2372-2377

  Aomatsu, Tomoki ^a   Yoden, Atsushi ^a   Matsumoto, Kyoichi ^b   Kimura, Emi ^b   Inoue, Keisuke ^a   Andoh, Akira ^c   Tamai, Hiroshi ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Mikuri Immunological Lab Co   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Biomarker; Children; Fecal calprotectin; Inflammatory bowel disease; Mucosal healing

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ECHOGRAPHY; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; ILEUM; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; ENDOSCOPY, GASTROINTESTINAL; FECES; FEMALE; HUMANS; ILEAL DISEASES; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SEVERITY OF ILLNESS INDEX;

EID: 79960945938     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1633-y     Document Type: Article

References (33)

1. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008;43:1-17. (Pubitemid 351324980)
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
3. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007; 42:16-25. (Pubitemid 46351421)
4. Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child. 2004;89:69-71. (Pubitemid 38122017)
5. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119:1113-1119. (Pubitemid 46871266)
6. Quail MA, Russell RK, Van Limbergen JE, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:756-759.
7. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes. 2009;2:221.
8. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child. 1995;73:354-355.
9. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56-66.
10. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25:247-255. (Pubitemid 46115394)
11. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831-2837.
12. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem. 1983;134:1-6. (Pubitemid 13051561)
13. Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn's disease activity. QJM. 2005;98:435-441. (Pubitemid 40796815)
14. Ashorn S, Honkanen T, Kolho KL, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:199-205.
15. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008;14:1392-1398.
16. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221-1229.
17. Joishy M, Davies I, Ahmed M, et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;48:48-54.
18. Diamanti A, Panetta F, Basso MS, Forgione A, Colistro F, Bracci F, Papadatou B, Francalanci P, Torroni F, Knafelz D et al. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis. 2010;16:1926-1930.
19. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
20. Ho GT, Lee HM, Brydon G, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678.
21. Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45:414-420. (Pubitemid 350307158)
22. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. (Pubitemid 43764536)
23. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-432. (Pubitemid 47193130)
24. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
25. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393-407.
26. Osada T, Ohkusa T, Yokoyama T, Shibuya T, Sakamoto N, Beppu K, Nagahara A, Otaka M, Ogihara T, Watanabe S. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis. 2010;16:192-197.
27. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512. (Pubitemid 39311530)
28. Minderhoud IM, Samsom M, Oldenburg B. What predicts mucosal inflammation in Crohn's disease patients? Inflamm Bowel Dis. 2007;13:1567-1572.
29. Puylaert JB. Ultrasonography of the acute abdomen: gastrointestinal conditions. Radiol Clin North Am. 2003; 41:1227-1242, vii.
30. Sturm EJ, Cobben LP, Meijssen MA, van der Werf SD, Puylaert JB. Detection of ileocecal Crohn's disease using ultrasound as the primary imaging modality. Eur Radiol. 2004;14:778-782. (Pubitemid 38678895)
31. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1746-1754.
32. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706-1713. (Pubitemid 350206297)
33. Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2005;94:1855-1858. (Pubitemid 43155608)